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Introduction
Overactive bladder (OAB) is deﬁned by urgency, with
or without urgency incontinence, usually with
increased daytime frequency and nocturia (1). OAB is
a chronic condition affecting 12–17% of the adult
population in Europe and North America (2–4).
Although antimuscarinic agents are the pharmacologi-
cal mainstay of OAB treatment (5,6), efﬁcacy and tol-
erability vary among agents and patients (7).
Fesoterodine is an antimuscarinic developed for
the treatment of the symptoms of OAB. Fesoterodine
is rapidly and extensively converted by non-speciﬁc
esterases to its active metabolite, 5-hydroxymethyl
tolterodine (5-HMT), which is also the active metab-
olite of tolterodine (8). The oxidation of tolterodine
to 5-HMT is mediated by cytochrome P450 (CYP)
2D6 in the liver, and because there is substantial in-
terindividual variability in CYP2D6 metabolic activ-
ity, extensive and poor metabolisers have markedly
different proportions of plasma tolterodine to
5-HMT following tolterodine administration (9). The
esterases that convert fesoterodine to 5-HMT do not
exhibit genotypic variations and they are not known
to be involved in any drug–drug interactions. Thus,
the pharmacokinetic variability among individuals
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SUMMARY
Aims: To evaluate the efﬁcacy and tolerability of ﬂexible-dose fesoterodine in sub-
jects with overactive bladder (OAB) who were dissatisﬁed with previous tolterodine
treatment. Methods: This was a 12-week, open-label, ﬂexible-dose study of
adults with OAB (‡ 8 micturitions and ‡ 3 urgency episodes per 24 h) who had
been treated with tolterodine (immediate- or extended-release) for OAB within
2 years of screening and reported dissatisfaction with tolterodine treatment. Sub-
jects received fesoterodine 4 mg once daily for 4 weeks; thereafter, daily dosage
was maintained at 4 mg or increased to 8 mg based on the subject’s and physi-
cian’s subjective assessment of efﬁcacy and tolerability. Subjects completed 5-day
diaries, the Patient Perception of Bladder Condition (PPBC) and the Overactive
Bladder Questionnaire (OAB-q) at baseline and week 12 and rated treatment satis-
faction at week 12 using the Treatment Satisfaction Question (TSQ). Safety and
tolerability were assessed. Results: Among 516 subjects treated, approximately
50% opted for dose escalation to 8 mg at week 4. Signiﬁcant improvements from
baseline to week 12 were observed in micturitions, urgency urinary incontinence
episodes, micturition-related urgency episodes and severe micturition-related
urgency episodes per 24 h (all p < 0.0001). Approximately 80% of subjects who
responded to the TSQ at week 12 reported satisfaction with treatment; 38%
reported being very satisﬁed. Using the PPBC, 83% of subjects reported improve-
ment at week 12 with 59% reporting improvement ‡ 2 points. Signiﬁcant
improvements from baseline (p < 0.0001) exceeding the minimally important dif-
ference (10 points) were observed in OAB-q Symptom Bother and Health-Related
Quality of Life (HRQL) scales and all four HRQL domains. Dry mouth (23%) and
constipation (5%) were the most common adverse events; no safety issues were
identiﬁed. Conclusion: Flexible-dose fesoterodine signiﬁcantly improved OAB
symptoms, HRQL, and rates of treatment satisfaction and was well tolerated in
subjects with OAB who were dissatisﬁed with prior tolterodine therapy.
What’s known
Fixed-dose clinical trials have shown that
fesoterodine 4 or 8 mg once daily signiﬁcantly
improves bladder diary variables and measures of
health-related quality of life compared with placebo
and that fesoterodine is generally well tolerated.
What’s new
This is the ﬁrst ﬂexible-dose trial of fesoterodine.
Dose escalation was based on subject and
physician assessment of efﬁcacy and tolerability,
which mimics clinical practice. Flexible-dose
fesoterodine was associated with a high rate of
self-reported treatment satisfaction, produced
signiﬁcant improvements in bladder diary variables
and measures of symptom bother and health-
related quality of life, and was generally well
tolerated.
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560 doi: 10.1111/j.1742-1241.2009.02035.xtreated with fesoterodine is lower. Moreover, all
antimuscarinic activity following fesoterodine admin-
istration is due to 5-HMT, whereas both tolterodine
and 5-HMT contribute to the antimuscarinic activity
of tolterodine.
Two previous randomised, double-blind, placebo-
controlled, ﬁxed-dose phase 3 studies demonstrated
that fesoterodine 4 or 8 mg once daily (qd) signiﬁ-
cantly improves OAB symptoms and measures of
health-related quality of life (HRQL) compared with
placebo (10–12). Moreover, compared with subjects
receiving placebo, a signiﬁcantly greater proportion
of subjects receiving fesoterodine 4 or 8 mg reported
a Treatment Response, a yes⁄no variable derived
from the validated four-point Treatment Beneﬁt
Scale (13). The availability of the two doses of fesote-
rodine provides an opportunity to establish an opti-
mal balance between efﬁcacy and tolerability in
individual patients. However, the ﬁxed-dose fesotero-
dine data currently available in the literature do not
provide clinicians with information regarding efﬁcacy
and tolerability with ﬂexible dosing to guide their
use in clinical practice. Furthermore, data on the
efﬁcacy and tolerability of fesoterodine in patients
who are not satisﬁed with tolterodine for OAB
would also be relevant to clinical practice.
The primary objective of this open-label study was
to assess the effect of a ﬂexible-dosing regimen of
fesoterodine on OAB symptoms and treatment satis-
faction in subjects with OAB who were dissatisﬁed
with previous tolterodine or tolterodine extended
release (ER) treatment. Secondary objectives included
evaluating the effect on measures of HRQL and other
patient-reported outcomes as well as the safety and
tolerability of fesoterodine therapy.
Subjects and methods
Study design
In this 12-week, multicentre, open-label, single-arm,
ﬂexible-dose study, the effect of fesoterodine on OAB
symptoms and treatment satisfaction was assessed in
adult subjects with OAB who were dissatisﬁed with
previous tolterodine or tolterodine ER therapy. This
study was conducted at 80 centres worldwide, with
centres in Asia, Europe, and North and Central Amer-
ica. The study was conducted in accordance with the
Good Clinical Practice guidelines and the Declaration
of Helsinki. The protocol was approved by the respec-
tive Institutional Review Boards⁄Independent Ethics
Committees, and all subjects provided written
informed consent before the start of the study.
Baseline OAB symptoms were assessed using a
5-day bladder diary during a 2-week screening per-
iod, before which any previous antimuscarinic medi-
cation was stopped. Subjects rated the sensation
associated with each micturition or urgency urinary
incontinence (UUI) episode in the diary using the
ﬁve-point Urinary Sensation Scale (USS; 1 = no
urgency, 2 = mild urgency, 3 = moderate urgency,
4 = severe urgency, 5 = UUI) (14). All enrolled sub-
jects were treated for 4 weeks with fesoterodine 4 mg
qd, taken in the morning. At week 4, dosage could
either be maintained at fesoterodine 4 mg qd or
increased to 8 mg qd for the remaining 8 weeks of
the study. Consistent with clinical practice, the deci-
sion to maintain or increase the dose of fesoterodine
was based on a discussion between the subject and
the investigator regarding their subjective assessment
of treatment efﬁcacy and tolerability.
Subjects
Eligible subjects were men and women aged
‡ 18 years with self-reported OAB symptoms for
‡ 3 months before screening with a mean micturi-
tion frequency of ‡ 8 micturitions per 24 h and
mean number of urgency episodes ‡ 3 per 24 h in a
5-day bladder diary at baseline (urgency episodes
were deﬁned as those with a USS rating ‡ 3). Sub-
jects had to rate their bladder condition as causing at
least ‘some moderate problems’ on the Patient Per-
ception of Bladder Condition (PPBC) questionnaire
at baseline. Subjects were also required to have been
treated with tolterodine or tolterodine ER for OAB
within 2 years of screening and to report being
‘somewhat dissatisﬁed’ or ‘very dissatisﬁed’ with tol-
terodine treatment on the Treatment Satisfaction
Question (TSQ), a single item from the validated
Overactive Bladder Satisfaction Questionnaire (15);
subjects are asked how satisﬁed they are with their
OAB medication and respond on a ﬁve-point Likert
scale. Subjects who had received prior OAB treat-
ment with ‡ 3 antimuscarinics (including toltero-
dine) within 12 months, or who had neurogenic
bladder, a history of acute urinary retention requir-
ing catheterisation, predominant stress urinary
incontinence, signiﬁcant pelvic organ prolapse, lower
urinary tract surgery within 6 months, signiﬁcant
hepatic or renal function impairment, or any contra-
indication to fesoterodine usage, were excluded from
the study. Subjects’ reasons for dissatisfaction with
previous tolterodine treatment were not collected.
Assessments
To assess efﬁcacy, subjects completed 5-day bladder
diaries at baseline and at 12 weeks. Subjects recorded
the time of every micturition and rated the sensation
associated with each micturition using the ﬁve-point
USS. Subjects rated satisfaction with fesoterodine
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completed several validated OAB-speciﬁc question-
naires at baseline and week 12, including the PPBC
(16), the Urgency Perception Scale (UPS) (17) and
the Overactive Bladder Questionnaire (OAB-q) (18).
The PPBC is a single-item six-point instrument used
by subjects to rate the severity of their bladder-
related problems: ‘My bladder causes me no (1), very
minor (2), minor (3), moderate (4), severe (5) or
many severe (6) problems’. The UPS is a three-point
scale; response options include: ‘usually not able to
hold urine’ (1), ‘usually able to hold urine if I go to
the toilet immediately’ (2) and ‘usually able to ﬁnish
what I am doing before going to the toilet’ (3). The
OAB-q comprises an eight-item Symptom Bother
scale and a 25-item HRQL scale with 4 domains
(Concern, Coping, Sleep and Social Interaction).
Safety and tolerability were assessed.
Primary end-points were change from baseline to
week 12 in number of micturitions, number of UUI
episodes (among subjects with a baseline UUI > 0),
and number of micturition-related urgency episodes
(deﬁned as those with a USS rating ‡ 3) per 24 h
and the percentage of subjects reporting treatment
satisfaction at week 12 (‘very satisﬁed’ or ‘somewhat
satisﬁed’ on the TSQ).
Secondary bladder diary end-points included
change from baseline to week 12 in nocturnal mictu-
ritions, severe micturition-related urgency episodes
(deﬁned as those with a UUS rating of ‡ 4), and fre-
quency-urgency sum (deﬁned as the sum of all USS
ratings) per 24 h. Additional secondary end-points
included change from baseline in PPBC, UPS and
OAB-q scores at week 12.
Safety and tolerability
All adverse events (AEs), whether directly observed
by the investigator, reported by the subject or result-
ing from investigator questioning of the subject
regarding their tolerance of study treatment, were
recorded during the entire study period. The causal-
ity (based on the investigator’s assessment), severity
and outcome of each AE were recorded.
Statistical analyses
A sample size of 400 subjects was calculated to pro-
vide a 5% level of precision in the 95% CI for the
percentage of subjects reporting treatment satisfac-
tion at week 12. The other primary end-points were
powered for 95%, resulting in an overall power of
85%. Statistical analyses of all efﬁcacy variables at
week 12 were performed using the full analysis set
(i.e. all subjects who took ‡ 1 dose of study drug
and contributed data to at least one baseline or post-
baseline efﬁcacy assessment). The last valid postbase-
line observation was carried forward to handle
missing efﬁcacy data at week 12. Descriptive statistics
and two-sided paired t-tests at the 5% signiﬁcance
level were used to analyse efﬁcacy end-points. Tolera-
bility analyses were performed based on the data
from all subjects who took at least one dose of study
drug. Subjects were not stratiﬁed by titration status
for the assessment of efﬁcacy or tolerability.
Results
Subjects
Subject disposition is shown in Figure 1. Subject
demographics are shown in Table 1. Most subjects
Figure 1 Subject disposition
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age was 60 years; three-quarters of the women were
postmenopausal. A total of 256 (50%) subjects
reported at least one episode of UUI at baseline,
including nearly one-ﬁfth (n = 22; 19%) of the men
and three-ﬁfths (n = 234; 59%) of the women. In
addition to prior treatment with tolterodine or tolte-
rodine ER, 216 subjects (42%) had received ‡ 1
other antimuscarinic prior to study enrolment. Nota-
bly, 67% of all male subjects in the study reported a
history of benign prostatic hyperplasia. Eleven sub-
jects included in this study did not report being dis-
satisﬁed with prior tolterodine treatment at the
beginning of the study; inclusion of these 11 major
protocol violators did not materially affect the study
results.
Of the 516 subjects who received at least 1 dose of
study drug and had at least one postbaseline assess-
ment, 255 (50%, excluding two subjects who started
with 8 mg) opted for dose escalation to fesoterodine
8 mg at week 4. The remaining subjects continued
receiving the 4-mg dose.
Efﬁcacy
OAB symptoms
Statistically signiﬁcant improvements from baseline
to week 12 were observed in mean number of
micturitions, UUI episodes and urgency episodes
(p < 0.0001 for all comparisons; Figure 2).
Statistically signiﬁcant improvements in nocturnal
Table 1 Baseline demographics and clinical
characteristics*
Men Women Total
Gender, n (%) 118 (23) 398 (77) 516
Age, mean ± SD (years) 64 ± 12 58 ± 14 60 ± 14
Range 19–83 19–90 19–90
Race, n (%)
White 92 (78) 303 (76) 395 (77)
Black 5 (4) 5 (1) 10 (2)
Asian 21 (18) 76 (19) 97 (19)
Other 0 14 (4) 14 (3)
Postmenopausal,
n (%)
NA 304 (76) NA
Past or present
BPH, n (%)
79 (67) NA NA
Incontinent at
baseline, n (%)
22 (19) 234 (59) 256 (50)
*Safety analysis set (equivalent to full analysis set).
UUI > 0 episodes on baseline diary.
BPH, benign prostatic hyperplasia; NA, not applicable.
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Figure 2 Number of (A) micturitions, (B) UUI episodes (for subjects reporting > 0 UUI episodes at baseline), (C)
urgency episodes, (D) nocturnal micturitions, (E) severe urgency episodes (for subjects reporting > 0 severe urgency
episodes at baseline) and (F) frequency-urgency sum per 24 h at baseline and at 12 weeks of fesoterodine treatment. Data
shown are mean ± standard deviation. UUI = urgency urinary incontinence. *p < 0.0001 vs. baseline
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quency-urgency sum were also observed at week 12
(p < 0.0001 for all comparisons; Figure 2). The
corresponding median % change from baseline to
week 12 was )22% for micturition frequency,
)100% for UUI episodes, )57% for urgency
episodes, )31% for nocturnal micturitions and
)94% for severe urgency episodes.
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Figure 5 Response distribution on the UPS at baseline and after 12 weeks of fesoterodine treatment. UPS = Urgency
Perception Scale
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At 12 weeks, 80% of subjects who responded to
the TSQ reported being satisﬁed with fesoterodine
treatment, with 38% of subjects being ‘very satis-
ﬁed’ (Figure 3). Mean PPBC scores improved
signiﬁcantly from 4.9 at baseline to 3.1 at week 12
(p < 0.0001). By week 12, 83% of subjects reported
improvement on the PPBC, with 59% of subjects
reporting improvement ‡ 2 points. The proportion
of subjects reporting severe or many severe prob-
lems was reduced from 68% at baseline to 12%
after 12 weeks, whereas the proportion reporting
no problems, very minor problems or minor
problems was increased from zero at baseline (as
required by the inclusion criteria) to 63% at
12 weeks (Figure 4).
Mean UPS scores improved signiﬁcantly from 1.8
at baseline to 2.4 at week 12 (p < 0.0001). UPS
scores improved in 49% of subjects, deteriorated
(post hoc analysis) in 2%, and were unchanged in the
remaining subjects. The proportion of subjects who
reported that they were usually not able to hold their
urine was reduced from 25% at baseline to 6% after
12 weeks. The proportion of subjects who reported
being able to ﬁnish what they were doing before
going to the toilet was increased from 6.8% at base-
line to 41% after 12 weeks (Figure 5).
The mean change in OAB-q Symptom Bother score
(29-point improvement) from baseline to week 12
was statistically signiﬁcant (p < 0.0001; Figure 6).
Mean changes in total HRQL (26-point improve-
ment) and all four HRQL domain (Concern, 29-point
improvement; Coping, 31-point improvement; Sleep,
25-point improvement; Social Interaction, 17-point
improvement) scores were also statistically signiﬁcant
at 12 weeks, compared with baseline (p < 0.0001;
Figure 6). The improvements for all scales and
domains were well above the minimally important
difference of 10 points, indicating that these changes
were clinically meaningful (19).
Safety and tolerability
Dry mouth (23%) and constipation (5%) were the
most frequently reported AEs (Table 2); most of
these were mild or moderate in severity. Urinary
retention requiring catheterisation was reported by
one woman receiving fesoterodine 8 mg who with-
drew from the study. Two women receiving the
4-mg dose were reported to have urinary retention
not requiring catheterisation; one withdrew from the
study. No cases of urinary retention occurred in
men. The overall withdrawal rate was 10% and the
rate of withdrawal due to treatment-emergent AEs
regardless of causality was 7%. There were no deaths
during the study; nine subjects (< 2%) reported
serious AEs, none of which was deemed to be
treatment related.
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Figure 6 Overactive Bladder Questionnaire (OAB-q) scores for total HRQL, the four HRQL domains, and Symptom
Bother are shown at baseline and after 12 weeks of fesoterodine treatment. A positive score change in total HRQL and its
domains indicates improvement; a negative score change in Symptom Bother indicates improvement. HRQL = health-
related quality of life. *p < 0.0001 vs. baseline
Table 2 Treatment-emergent adverse events reported by
‡ 1% of subjects (all causality)
Adverse
event, n (%) n = 516
Severity, n
Mild Moderate Severe
Dry mouth 120 (23.3) 98 16 6
Constipation 25 (4.8) 16 7 2
Headache 19 (3.7) 14 4 1
Diarrhoea 12 (2.3) 10 2 0
Abdominal
pain, upper
11 (2.1) 6 3 2
Dizziness 6 (1.2) 5 1 0
Dry eye 6 (1.2) 6 0 0
Dysuria 6 (1.2) 3 1 2
Nausea 6 (1.2) 5 1 0
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This is the ﬁrst phase 3b study of fesoterodine and
the ﬁrst fesoterodine study to employ ﬂexible dosing.
The results presented here show that ﬂexible-dose
fesoterodine signiﬁcantly improved several bladder
diary variables as well as subjects’ assessment of their
bladder-related problems, urgency, symptom bother
and HRQL in subjects who reported dissatisfaction
with previous tolterodine treatment. Additionally,
approximately 80% of respondents in the current
study reported satisfaction with fesoterodine treat-
ment at week 12. These ﬁndings were expected con-
sidering the results of two previous ﬁxed-dose
placebo-controlled phase 3 clinical trials that demon-
strated signiﬁcantly greater improvements in bladder
diary variables and HRQL measures and signiﬁcantly
greater rates of self-reported treatment response in
subjects who received fesoterodine 4 or 8 mg com-
pared with those who received placebo (10–12).
Fesoterodine was well tolerated.
Approximately half of the subjects in this study
opted to escalate their fesoterodine dose to 8 mg
at week 4. This decision was based on discussion
with the investigator about efﬁcacy and tolerability,
as assessed subjectively by the subject and investi-
gator. The availability of two doses allows for indi-
vidualisation of patient care. A pooled, post hoc
analysis of the two phase 3 trials showed that feso-
terodine 8 mg was signiﬁcantly more efﬁcacious
than fesoterodine 4 mg in improving UUI episodes,
mean voided volume per micturition, continent
days per week (extrapolated from 3-day diaries),
and subject-reported Treatment Response at week
12, indicating an apparent efﬁcacy dose–response
effect on these end-points (20). Thus, dose escala-
tion may allow for improved outcomes in those
patients who report good tolerability and desire
greater symptom relief. However, we did not assess
whether there was a dose–response effect in this
analysis.
This was an open-label study. Open-label trials
reﬂect clinical practice; however, they have inherent
limitations. For example, open-label studies are
unable to account for placebo effects, which are often
substantial in randomised placebo-controlled clinical
trials of antimuscarinics for OAB (21). Another limi-
tation is that this study was not designed a priori to
compare in its primary analysis efﬁcacy and tolerabil-
ity in subjects who received the 4-mg dose through-
out the study with subjects who escalated to the
8-mg dose at week 4, and comparisons by dose are
limited by the ﬂexible dosing design. Differences in
efﬁcacy and tolerability between subjects who did
and did not opt for dose escalation will be assessed
at time points before and after dose escalation in post
hoc analyses. Additionally, we did not capture reasons
why subjects did or did not opt for dose escalation.
However, this study is meant to reﬂect real-world
clinical conditions. Presumably, this study provides
information regarding fesoterodine efﬁcacy and toler-
ability that is more relevant to real-world clinical
practice than ﬁxed-dose studies, because the ﬁnal
dose each subject received was determined by a dis-
cussion between the subject and investigator about
efﬁcacy and tolerability rather than random assign-
ment. As in real-world clinical practice, the reasons
underlying the decision of whether or not to increase
the dose likely varied between individuals but
reﬂected optimisation of the balance between efﬁcacy
and tolerability. Further, detailed information about
the reason for dissatisfaction with previous toltero-
dine treatment was not collected, which limited our
ability to determine what aspects of fesoterodine
contributed to the high rate of treatment satisfaction
(i.e. efﬁcacy and⁄or tolerability) in this population or
predict which reasons might lead to dissatisfaction.
Conclusions
When used with a ﬂexible-dosing regimen in this
open-label study, fesoterodine signiﬁcantly improved
OAB symptoms and HRQL measures and reduced
OAB-related symptom bother in subjects with OAB
who had been dissatisﬁed with previous tolterodine
or tolterodine ER treatment. Approximately 80% of
subjects reported treatment satisfaction and about
50% of subjects opted to receive the higher 8-mg
dose after initial 4-mg treatment. Fesoterodine was
well tolerated.
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